Abstract: The present invention relates to novel use of koumine, an alkaloid monomer from Gelsemium elegans Benth., or a pharmaceutically acceptable salt thereof, and more particularly to use of koumine or its pharmaceutically acceptable salt in the preparation of a medicament for the treatment of inflammatory bowel disease.

Abstract: The application relates to a compound of Formula (I): which modulates the activity of ALK or SRPK, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which ALK or SRPK plays a role.

Abstract: Compositions and methods for the treatment of pruritic ani and anal fissures are described. The compositions include one or more of Calamine (USP) or zinc oxide (ZnO), aluminum hydroxide (Al(OH)3) or kaolin, glycerin, and menthol (or any compound which activates the menthol receptor (TRPM8)). The composition does not contain any hydrocarbon-based pharmaceutical carrier such as petroleum jelly, white petrolatum, mineral oil, hard paraffin, soft paraffin, microcrystalline wax, ceresine, or hard fats. Methods of treating pruritic ani and anal fissures by topical application(s) of the compositions to affected perianal or anal epidermis are also described.

Abstract: A chlorin compound, and a preparation and use thereof, related to medicine. The chlorin compound is represented by formula (I), or a salt, a stereisomer, a hydrate, a solvate or a prodrug thereof.

Abstract: A method of macular disease treatment (500) may include introducing nanocapsules into a body of a patient (502). The nanocapsules may be introduced such that the nanocapsules circulate through at least a portion of a body of the patient. A therapeutic substance and a colorant may be encapsulated into the nanocapsules. After a portion of the nanocapsules enters choroidal neovessels of an eye of the patient, the method may include emitting a pulsed laser radiation through a pupil of the eye (504). Additionally, after a portion of the nanocapsules enters choroidal neovessels of an eye of the patient, the method may include heating the portion of the nanocapsules present in the eye (506) such that at least a portion of the nanocapsules transfer phase and release the therapeutic substance.

Abstract: The disclosure relates to modulating pyruvate kinase and provides novel chemical compounds useful as activators of PKR, as well as various uses of these compounds. PKR activating compounds are useful in the treatment of diseases and disorders associated with PKR and/or PKM2, such as pyruvate kinase deficiency (PKD), sickle cell disease (SCD), and thalassemia.

Abstract: The invention relates to compounds and methods for restoring or preserving cholesterol efflux in a cell infected with Human Immunodeficiency Virus (HIV) by preventing or decreasing an interaction between Negative Regulatory Factor (Nef) protein and Calnexin protein, and methods for screening for such compounds.

Abstract: This application relates to compounds of formulae (I) and (II) and compositions thereof useful as inhibitors of PIM kinases. Also provided are methods of synthesis and methods of use of PIM inhibitors in treating individuals suffering from cancerous malignancies.

Abstract: The present invention provides amphiphilic telodendrimers that aggregate to form nanocarriers characterized by a hydrophobic core and a hydrophilic exterior. The nanocarrier core may include amphiphilic functionality such as cholic acid or cholic acid derivatives, and the exterior may include branched or linear poly(ethylene glycol) segments. Nanocarrier cargo such as hydrophobic drugs and other materials may be sequester in the core via non-covalent means or may be covalently bound to the telodendrimer building blocks. Telodendrimer structure may be tailored to alter loading properties, interactions with materials such as biological membranes, and other characteristics.

Abstract: The invention relates to compounds and methods for restoring or preserving cholesterol efflux in a cell infected with Human Immunodeficiency Virus (HIV) by preventing or decreasing an interaction between Negative Regulatory Factor (Nef) protein and Calnexin protein, and methods for screening for such compounds.

Abstract: A method for inhibiting biofilm formation by bacteria on a surface or disrupting existing biofilm on a surface, including contacting the surface or existing biofilm with 2-(indolin-2-yl)-1H-ind, di(1H-indol-3-yl)methane and 1,1?-biindole, or any combination thereof.

Abstract: The application relates to a compound of Formula (I): which modulates the activity of ALK or SRPK, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which ALK or SRPK plays a role.

Abstract: A surgical laser system can include a fluorescent sensing assembly for detecting fluorescent signal from a tissue under a surgical operation of the surgical laser system. The surgical laser system can include an aiming laser assembly, which can be configured to provide excitation energy for the fluorescent process. The surgical laser system can include an infrared sensing assembly, which can provide temperature related data, for example, to prevent damages to the tissue due to overheating. The surgical laser system can be configured to use the off-time of the surgical laser for tissue sensing. Data from tissue sensing can be further analyzed by an integrated robotic surgical system to provide a highly precise surgical procedure.

Abstract: The present invention is directed to a method of controlling a pest comprising applying an effective amount of one or more terpendoles to the pest or an area in need of pest control. The present invention is further directed to a method of controlling a pest comprising applying an effective amount of one or more compounds having the following chemical structure to the pest or an area in need of pest control.

Abstract: The present application relates generally to a method and a composition matter that provides a rapid and potent antimicrobial photodynamic inactivation (aPDI) of pathogenic bacteria that express high-affinity cell-surface hemin receptors (CSHRs) using Ga(III)-protoporphyrins IX (GaPpIX or Ga-PpIX). The invention provides an effective treatment option for infections of skin or body cavities that are accessible to visible-light irradiation, such as a handheld LED array emitting visible light (405 nm), especially for infections caused by Staphylococcus aureus, Methicillin-resistant Staphylococcus aureus (MRSA), pathogenic staphylococci, Streptococcus mutans, S. pneumoniae, S. pyogenes, streptococci, corynebacteria, mycobacteria, and Bacillus anthracis.

Abstract: A process is described for the preparation of freeze-dried pharmaceutical compositions of mitomycin C, which are characterized by high stability and can be rapidly reconstituted to form solutions.

Abstract: The invention relates to compounds and methods for restoring or preserving cholesterol efflux in a cell infected with Human Immunodeficiency Virus (HIV) by preventing or decreasing an interaction between Negative Regulatory Factor (Nef) protein and Calnexin protein, and methods for screening for such compounds.

Abstract: Disclosed are methods for the preparation of Tecovirimat for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by the orthopoxvirus.

Abstract: The application relates to a compound of Formula (I): which modulates the activity of ALK or SRPK, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which ALK or SRPK plays a role.

Abstract: The invention provides bridged diindole compounds, related pharmaceutical compositions and methods of use thereof, for the prevention, palliation and/or treatment of nervous system disorders.

Abstract: Compounds and methods are providing involving RebH variants with improved properties. directed evolution based on random mutagenesis was employed to generate a series of RebH variants. RebH variants with improved thermostability and increased activity at elevated temperatures were generated.

Abstract: This document provides methods and materials involved in treating bladder cancer. This document also provides methods and materials involved in identifying bladder cancer patients likely or unlikely to respond to treatment (e.g., BCG therapy).

Abstract: A method of making a bacteriochlorin is carried out by condensing a pair of compounds of Formula II to produce the bacteriochlorin, wherein R is an acetal or aldehyde group. The condensing may be carried out in an organic solvent, preferably in the presence of an acid. The bacteriochlorins are useful for a variety of purposes such as active agents in photodynamic therapy, luminescent compounds in flow cytometry, solar cells, light harvesting arrays, and molecular memory devices.

Abstract: Provided are compositions, kits, and methods for detecting a vesicle comprising a membrane permeable marker that is converted into a detectable marker inside the vesicle.

Abstract: A system for treatment of tumors includes a vessel having a photosensitizing agent therein, a delivery device for communicating the photosensitizing agent from the vessel to tumor tissue, a light source for radiating the tumor tissue after the delivery device has delivered the photosensitizing agent to the tumor tissue, a catheter having at least one inflatable balloon positioned thereon, and a fluid source that repeatedly inflates and at least partially deflates the inflatable balloon such that a resecting outer surface of the balloon contacts the radiated tumor tissue and resects the tissue.

Abstract: A targeting thymidine kinase photosensitizer and pharmaceutical composition and use for cancer treatment thereof is provided, which improves the selectivity of photosensitizers to tumor cells, has better tolerance, can reach maximum blood concentration in 24 hours, has a bigger conjugated system, a longer absorption wavelength and an advantage in treating depth tumors; the wavelength area does not need to consume much energy of a light-output device and even LEDs can be used, which render PDT more practical and economical. The targeting thymidine kinase photosensitizer can be used for diagnosis and for treating prostatic carcinoma via the guidance of fluorescence imaging. The pharmaceutical composition uses a combination of a chemotherapeutic agent and the targeting thymidine kinase photosensitizer, which further improves the therapeutic effect of the PDT method, expands the application range for tumors and has good effects on metastatic tumors as well.

Abstract: A method of making a bacteriochlorin is carried out by condensing a pair of compounds of Formula II to produce the bacteriochlorin, wherein R is an acetal or aldehyde group. The condensing may be carried out in an organic solvent, preferably in the presence of an acid. The bacteriochlorins are useful for a variety of purposes such as active agents in photodynamic therapy, luminescent compounds in flow cytometry, solar cells, light harvesting arrays, and molecular memory devices.

Abstract: The method of detecting bladder cancer by optical analysis of bodily fluids utilizes optical techniques to determine a concentration of porphyrin in a patient's bodily fluid sample. The patient is administered 5-aminolevulinic acid and, approximately eight hours later, a bodily fluid sample is collected from the patient, and this bodily fluid sample is optically analyzed to measure a concentration of porphyrin therein. Optical analysis is preferably performed by laser-induced fluorescence spectroscopy. If the measured concentration of porphyrin is approximately three times a pre-determined porphyrin concentration for a healthy person of the same age as the patient, then the patient is diagnosed with bladder cancer.

Abstract: There are provided an apparatus and a method for blocking abnormal conduction in the cardiac muscle using a photodynamic therapy or for treating arrhythmia. There is provided a catheter ablation apparatus for the treatment of arrhythmia using a photodynamic therapy, comprising a catheter leading a photoradiation unit to an abnormal electrical conduction site or a hyperexcitability occurring site in the cardiac muscle of a test subject in which a photosensitizer is present by administering the photosensitizer beforehand and which causes arrhythmia, means for generating a light ray with which the abnormal electrical conduction site or the hyperexcitability occurring site is irradiated, and means for transmitting the light ray to the abnormal electrical conduction site or the hyperexcitability occurring site, wherein the photosensitizer used is a water-soluble chlorine-based photosensitizer and the light ray used is a light ray having an excitation wavelength equal to that of the photosensitizer.

Abstract: In one aspect, the invention is directed to a method of characterizing a mechanism of action of a combination of agents. The method comprises contacting a plurality of populations of cells with a combination of agents to be assessed, wherein each population of cells have one gene of interest targeted by a small hairpin RNA (shRNA) and wherein the gene of interest regulates cell death and a plurality of genes that regulate cell death are targeted in the plurality of populations of cells. A responsiveness of each population of cells to the combination of agents is determined, thereby obtaining an shRNA signature of the combination of agents so as to identify one or more genes that mediate a response to the combination of agents, thereby characterizing the mechanism of action of the combination of agents.

Abstract: In some embodiments, the present invention provides methods of treating oxidative stress in a subject by administering a therapeutic composition to the subject. In some embodiments, the therapeutic composition comprises a carbon nanomaterial with anti-oxidant activity. In some embodiments, the anti-oxidant activity of the carbon nanomaterial corresponds to ORAC values between about 200 to about 15,000. In some embodiments, the administered carbon nanomaterials include at least one of single-walled nanotubes, double-walled nanotubes, triple-walled nanotubes, multi-walled nanotubes, ultra-short nanotubes, graphene, graphene nanoribbons, graphite, graphite oxide nanoribbons, carbon black, oxidized carbon black, hydrophilic carbon clusters, and combinations thereof. In some embodiments, the carbon nanomaterial is an ultra-short single-walled nanotube that is functionalized with a plurality of solubilizing groups.

Abstract: A stable micronized monoclinic form of asenapine maleate is described, which comprises 5% by weight or less of orthorhombic form or any other crystalline form of asenapine maleate, wherein the asenapine maleate has a particle size distribution characterized by a d90 equal to or below 40 ?m. Processes for preparing the stable micronized monoclinic form of asenapine maleate are also described. Formula (I).

Abstract: There are provided, inter alia, derivatives of seriniquinone and methods useful for the treatment of cancer, and in particular treatment of melanoma and prostate cancer.

Abstract: The present invention relates to a liposome composition comprising 0.001 to 5% by weight of conjugate of lysophophatidylcholine and chlorin e6, 1 to 10% by weight of sucrose laurate, 0.1 to 5% by weight of sodium stearoyl glutamate, 1 to 10% by weight of PEG-5 rapeseed sterol, 1 to 20% by weight of medium-chain triglyceride, 1 to 10% by weight of vegetable oil, 0.1 to 5% by weight of sodium deoxycholate, 3 to 10% by weight of glycerin and the balance of water, and a skin care composition comprising the same. The liposome composition of the present invention is very effective in the treatment of acne.

Abstract: Disclosed is asenapine phosphate of formula (I) and its enantiomer (I) which can be used to prepare asenapine maleate. Further disclosed is a monoclinic crystalline form of asenapine maleate.

Abstract: Methods of stimulating an increase in biomass by stimulating the growth, lifespan and/or reproduction of organisms such as fungi, algae, plants, and other aquatic organisms are provided by applying an effective amount of functionalized fullerenes. For example, polyhydroxy fullerenes are effective at low levels of promoting the increase in biomass.

Abstract: Provided herein are novel fluoroergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1D and/or the 5-HT1B receptor, without agonizing the 5-HT2B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the adrenergic alpha2A and/or the alpha2B receptors using the compounds and compositions disclosed herein.

Abstract: The invention relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3 and R4 are defined herein, and their use for the treatment of hepatitis C viral infection.

Abstract: Compound of Formula I: are described, along with compositions containing the same and methods of use thereof.

Abstract: The present invention is directed to novel tetracyclic heteroatom containing derivatives, pharmaceutical compositions containing them, their use in the treatment of disorders mediated by one or more sex steroid hormone receptors and processes for their preparation.

Abstract: A composition comprising an active ingredient selected from the group of 5-aminolevulinic acid or a pharmaceutically acceptable salt or derivative thereof; and an aqueous carrier comprising at least one absorption enhancer, an anesthetic, hyaluronic acid and at least one acid selected from the group consisting of glycolic acid and lactic acid. The composition is useful in a photodynamic method of treating skin disorders.

Abstract: Novel crystalline salts of Asenapine (I) with organic di-acids and tri-acids and to methods of their preparation are disclosed along with related pharmaceutical compositions and methods of treating psychotic diseases or disorders.

Abstract: An energy treatment system to treat a patient includes an energy delivery device having a plurality of energy emitters used in combination with an energy activatable drug. A mask can be used to define a treatment area. Energy from the energy emitters passes through an optical window of the mask to activate a cosmetically and/or therapeutically effective amount of the activatable drug at the target site to bring about a desired change of tissue, for example, to reduce visibility of one or more blood vessels, while energy from the energy emitters directed outside of the target site is blocked by the mask.

Abstract: Various porphyrin compounds comprising one or more pyridone moieties, intermediates thereof, compositions thereof, and, methods of making and using thereof.

Abstract: Compounds of the general structural formula (I) and (II) and use of the compounds and salts and hydrates thereof, as therapeutic agents are disclosed. Treatable diseases and conditions include cancers, inflammatory diseases and conditions, and immunodeficiency diseases. (I), (II).

Abstract: The invention relates to compounds of the formula (1), to a method for producing compounds of the formula (1), to the use of the compounds in electronic devices and to electronic devices containing compounds according to formula (1), preferably as electron transport materials, as matrix materials, as electron blocking materials or as emitting materials.

Abstract: Provided is an antimalarial drug which is useful for prevention and treatment of infectious diseases caused by malaria parasites. A preventive and/or therapeutic agent for malaria, which contains, as an active ingredient, 5-aminolevulinic acid (ALA), a derivative thereof, or a pharmacologically acceptable salt thereof, is used.

Abstract: Methods of treating metabolic stress disorders are disclosed that include administering to a subject a therapeutically effective amount of a composition that specifically inhibits the expression or activity of a mixed lineage kinase (MLK). Also disclosed are methods of identifying candidate compounds for treatment of metabolic stress disorders and methods of diagnosing metabolic stress disorders.

Abstract: Peptides and compounds are provided that function as EWS-FLI1 protein inhibitors. The peptides and compounds have utility in the treatment of Ewing's sarcoma family of tumors. Also provided are methods of preparing the compounds and assays for identifying inhibitors of EWS-FLI1 protein.

Abstract: There are provided, inter alia, derivatives of seriniquinone and methods useful for the treatment of cancer, and in particular treatment of melanoma and prostate cancer.